ENDOMETRIOSIS IN PERIMENOPAUSAL TRANSITION PERIOD AND IN POSTMENOPAUSE: CLINICAL, DIAGNOSTIC AND THERAPEUTIC ASPECTS

Objectives - efficiency assessment of the dienogest (Visan^) in treatment of perimeopausal patients with adenomyosis and postmenopausal women, in whom the adenomyosis was newly diagnosed. Material and methods. Included in the study, there were 64 patients (aged 45-52 years) who had undergone the surgical treatment of adenomyosis followed by the dienogest treatment at a dose of 2 mg, and 47 women in the age of 54-57 years with newly diagnosed adenomyosis in the course of menopausal hormone therapy (MHT). All patients received 2 mg of dienogest (Visannе, Bayer) during the period of 3-6 months. Medical checkup was performed in 3 and 6 months after initiation of treatment. Results and Discussion. The remarkable reduction in clinical manifestations and improvement of uterine walls structure was registered in both groups of patients in 3 months of treatment. However, in 25% of patients the echographic changes remained significant. In 6 months all the patients had a sustained remission and amenorrhea. Conclusion. In the course of investigation the dienogest (Visan^) at a dose of 2 mg revealed high efficacy in treatment of endometriosis in late perimeopausal and postmeopausal patients with a diagnosed abnormal uterine bleeding associated with adenomyosis.